1. Home
  2. PFSA vs BIVI Comparison

PFSA vs BIVI Comparison

Compare PFSA & BIVI Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

PFSA

Profusa Inc.

N/A

Current Price

$2.97

Market Cap

8.9M

Sector

Health Care

ML Signal

N/A

Logo BioVie Inc.

BIVI

BioVie Inc.

HOLD

Current Price

$1.13

Market Cap

8.5M

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
PFSA
BIVI
Founded
2009
2013
Country
United States
United States
Employees
N/A
N/A
Industry
Medical/Dental Instruments
Biotechnology: Pharmaceutical Preparations
Sector
Health Care
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
8.9M
8.5M
IPO Year
N/A
N/A

Fundamental Metrics

Financial Performance
Metric
PFSA
BIVI
Price
$2.97
$1.13
Analyst Decision
Analyst Count
0
0
Target Price
N/A
N/A
AVG Volume (30 Days)
241.9K
99.6K
Earning Date
04-02-2026
02-06-2026
Dividend Yield
N/A
N/A
EPS Growth
N/A
N/A
EPS
N/A
N/A
Revenue
N/A
N/A
Revenue This Year
N/A
N/A
Revenue Next Year
N/A
N/A
P/E Ratio
N/A
N/A
Revenue Growth
122.22
N/A
52 Week Low
$2.90
$1.06
52 Week High
$957.00
$19.50

Technical Indicators

Market Signals
Indicator
PFSA
BIVI
Relative Strength Index (RSI) 92.02 41.89
Support Level $0.05 $1.06
Resistance Level $4.22 $1.21
Average True Range (ATR) 0.15 0.09
MACD 0.34 0.00
Stochastic Oscillator 70.34 25.00

Price Performance

Historical Comparison
PFSA
BIVI

About PFSA Profusa Inc.

Profusa Inc is a clinical-stage digital health and medical technology company focused on developing biosensing solutions to improve health outcomes for patients with a variety of different diseases and conditions. The Company's technology enables the development of bioengineered sensors that are designed to become one with the body to detect and continuously transmit actionable, clinical-grade data for personal and medical use. The Company's first offering in the European Union, the Lumee Oxygen Platform, is designed to report reliable tissue oxygen levels at various regions of interest, both acutely and long-term.

About BIVI BioVie Inc.

BioVie Inc is a clinical-stage company developing drug therapies to treat chronic debilitating conditions including liver disease and neurological and neuro-degenerative disorders and certain cancers. The company is conducting a potentially pivotal Phase 3 randomized, double-blind, placebo-controlled, parallel-group, multicenter study to evaluate NE3107 in patients who have mild to moderate Alzheimer's disease. BIV201 has the potential to improve the health of thousands of patients suffering from life-threatening complications of liver cirrhosis due to hepatitis, non-alcoholic steatohepatitis and alcoholism.

Share on Social Networks: